Ever wish you could see inside the brains of Wall Street’s smartest minds? Well, that’s impossible. But WallStreetZen’s Strong Buy Stocks from Top Wall Street Analysts feature is the next best thing.
It’s a premium feature on our site, but we’ve unlocked a FREE sampling below:
- Analysts expect Cellebrite DI Ltd’s (NASDAQ: CLBT) growth expansion to continue.
-
Wix.com Ltd (NASDAQ: WIX) is our Stock of the Week — keep reading to find out why.
- Find out why JPMorgan is bullish on HubSpot Inc (NYSE: HUBS)
How about a bit of cyber-sleuthing? Cellebrite DI Ltd is in the business of digital intelligence and forensics. The company’s products allow law enforcement, enterprises, and government agencies to access, decode, and analyze digital evidence found on mobile devices, cloud services or even encrypted applications. To boot, the business also offers AI-driven analytics and automation tools — and it is seeing increased adoption across the world.
Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $19.66 — get current quote >
Max 1-year forecast: $28.00
Why we’re watching:
- Wall Street analysts are quite bullish on CLBT stock — 3 researchers deem it a Strong Buy, 2 rate it a Buy, and none have given it a Hold, Sell, or Strong Sell rating. See the ratings
- In addition, the average forecast for Cellebrite DI Ltd stock sits at $25.80 — equating to a pretty significant 31.23% upside.
- JP Morgan equity researcher Brian Essex (a top 10% rated analyst) reiterated a Strong Buy rating on February 11, ahead of the company’s Q4 and FY 2024 earnings call. Essex also increased his price target from $24 to $28.
- The analyst said they expect the company's growth acceleration to continue. In addition, Essex predicted that Cellebrite DI's continuing platform expansion, stronger government penetration, and migration to its subscription platform will lead to improved long-term fundamental strength.
- A similar sentiment was echoed by Needham’s Mike Cikos (a top 2% rated analyst), who maintained a Buy rating after the company released the report on February 14. The earnings call saw a double beat. Cikos also maintained a $28 price target.
- Our proprietary quant rating system has ranked CLBT in the top 5% of stocks when evaluating 115 factors — indicating a high likelihood of beating the market.
- Despite marking a 12.93% loss on a year-to-date (YTD) basis, Momentum remains CLBT’s strongest Component Grade rating. The stock is still up 68.39% compared to this time last year — so now might be an opportune time to buy the dip. (See all 7 Zen Component Grades here >)

Zen Rating: A (Strong Buy) — see full analysis >
Recent Price: $198.11 — get current quote >
Max 1-year forecast: $300.00
Why we’re watching:
- It’s our Stock of the Week — Zen Investor Editor-in-Chief Steve Reitmeister gave WIX stock a nod on Monday on account of promising growth metrics and a strong track record of outperforming earnings estimates. You can check out his article here. Here’s a closer look at his rationale:
- The business has managed to significantly increase its average revenue per user (ARPU). Moreover, it ranks in the top 4% of stocks when looking at Growth Component Grade scores, and the top 6% when looking at Financials.
- In addition, Wix.com has beat analyst estimates for earnings per share (EPS) by an average of 17% when looking at the last 4 quarters.
- Despite such promising data points, WIX shares are still trading some 19% off of a recent late-January high.
- Among the 16 equity researchers who track the stock and issue ratings for it, WIX is a consensus Strong Buy. As noted by our Editor-in-Chief, even the average 12-month price forecast of $251.56 implies a pretty significant 26.98% upside — and some of Wall Street’s top analysts are even more optimistic.
- Our Zen Ratings analysis, which takes into account 115 factors correlated with outsized returns, gives Wix.com stock an overall rating of A, placing it in the top 5% of the 4,600+ equities we track. In fact, it actually ranks in the top 2% — and as Steve put it, there are really no particular weaknesses at play here. (See all 7 Zen Component Grades here >)

In contrast with Freshworks, we have HubSpot — a large, well-established CRM and marketing automation business. With a subscription-based model that drives steady revenue growth and the ever-increasing popularity of automation tools, HubSpot is well-positioned to see further growth in the rest of 2025.
Zen Rating: B (Buy) — see full analysis >
Recent Price: $770.95 — get current quote >
Max 1-year forecast: $980.00
Why we’re watching:
- HubSpot has earned broad analyst support. Of the 23 analysts who track it, 12 deem it a Strong Buy, 7 rate it a Buy, and 4 rate it a Hold. See the ratings
- After the company’s Q4 and FY 2024 earnings report, JPMorgan’s Mark Murphy (a top 10% rated analyst) called Q4 "another quarter of differentiated performance”, reiterated a prior Strong Buy rating, and increased his price target for HUBS stock from $725 to $825.
- Looking ahead, the analyst told readers that JP Morgan continues to see "various positive vectors across the business."
- In addition, JP Morgan is encouraged by the potential for accelerating growth rates off what HubSpot management expects to be "a fiscal trough in Q1 2025."
- HubSpot stock carries an overall Zen Rating of B — placing it in the top 20% of the 4600+ stocks that our system tracks.
- The Zen Rating consists of 7 Component Grade ratings, and Growth, which carries an A rating, is HubSpot’s strong suit, indicating a high potential for expanding margins, EPS growth, and sales acceleration. (See all 7 Zen Component Grades here >)

What to Do Next?